- Detail
- Parameters
National drug
National "Nine Five" key scientific projects (research) program
State "15" major scientific and technological projects (863) topic
Intellectual property rights
[Product Overview]
In 2011, after research and clinical development and testing for 18 years, the first one in cardiac surgical method to evaluate the safety and efficacy of myocardial protection class of innovative medicines - four clinical trials of large sample injection is completed, said Austrian cardiomyopeptidin, officially listed size. This medicine is only for domestic listed cardiac surgery patients bring health gospel, but also to fill the domestic use of biological activity to protect myocardial cells, myocardial injury repair in the field blank.
[Product name] Common name: injection cardiomyopeptidin
Product name: apart Miding
English name: Cardiomyopeptide for Injection
Pinyin: Zhusheyong Xinjitai
[Approval No.] H20052173 Zhunzi
The main components of this product is the main component extracted from healthy young pig ventricular myocytes in polypeptide active substance having a weight average molecular weight of less than 5000 Daltons.
【Product Characteristics This product is white or light yellow freeze-dried lumps or powder.
Indications can be used as a cardiac surgery perioperative myocardial protection adjuvant drug, which is based on existing clinical study showed that the use of cardiomyopeptidin in cardiac surgery may improve perioperative myocardial ultrastructure, but for Cardiomyopeptidin improving the overall benefit surgical patients, cardiac function, etc. is unclear. The product is cardioprotective innovative drugs, the active ingredient is a group of small peptides having biological activity, can act directly on myocardial cells, promote myocardial repair in a variety of damaging factors, is the first by cardiac surgical method to evaluate its safety, innovation cardioprotective drug effectiveness.
【Product Features】
Injection cardiomyopeptidin is 18-year research and development, said Austrian class of innovative medicines with national intellectual property rights, its main role is in heart valve replacement, when bypass surgery, myocardial injury will be injected with the peptide on myocardial repair damaged myocardium cell effect is obvious, shorter operative recovery time, but also increase the probability of successful operation.
November 2005, injection Cardiomyopeptidin State Food and Drug Administration issued a new drug certificate and production approval. In November 2006, the Ministry of Science released 2006 National Torch Program to declare the results show, said Austrian Group successfully developed the country a class of drugs - injectable cardiomyopeptidin list.
Experiments by four spot in the country more than 10 major cardiovascular hospital injectable cardiomyopeptidin results showed that CMP myocardial injury has protective effects, can significantly reduce the degree of myocardial damage, and shorten recovery time after surgery.
Jane Austrian injection was listed as the national "Nine Five" key scientific and technological projects cardiomyopeptidin project, 863, has won state invention patents, to declare an international PCT and four national patents.
